• Policy
• The results of the PVA improvement plan study were disclosed
• by Lee, Tak-Sun Apr 12, 2023 05:54am

• Policy
• 16% of PVA-applied products cut more than 2 times
• by Lee, Tak-Sun Apr 12, 2023 05:54am

• Policy
• The alternative drug pricing system will be improved
• by Nho, Byung Chul Apr 12, 2023 05:53am

• Policy
• Leukemia Scemblix·Onureg passed the Evaluation Committee
• by Lee, Tak-Sun Apr 11, 2023 06:11am

• Policy
• 3 combination DM drug is cheaper than the 2 combi
• by Lee, Tak-Sun Apr 10, 2023 05:53am

• Policy
• Reimb review for Pompe disease drug Nexviazyme underway
• by Lee, Tak-Sun Apr 10, 2023 05:53am

• Policy
• Only a few cold drugs will be subject to PVA negotiations
• by Lee, Tak-Sun Apr 10, 2023 05:52am

• Policy
• Generics for Forxiga will be released simultaneously on the
• by Lee, Tak-Sun Apr 6, 2023 05:53am

• Policy
• Government's drug pricing policy
• by Lee, Jeong-Hwan Apr 5, 2023 05:48am

• Policy
• Countdown to initial non-face-to-face treatment
• by Lee, Jeong-Hwan Apr 5, 2023 05:48am